Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors

Tong T. Zhao, Diane Trinh, Christina L. Addison et al. · 2010

Read Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors by Tong T. Zhao, Diane Trinh, Christina L. Addison et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012563.txt.

Description

Tong Zhao, Diane Trinh, Christina Addison and colleagues paired a cholesterol drug with vessel blockers against cancer, in a 2010 PLOS ONE paper. Lovastatin, a statin, blocks building of mevalonate, a hub molecule in cell chemistry. The team had already seen it hinder the epidermal growth factor receptor; here they tested its action on the VEGF receptor pathway that feeds tumors.

Lovastatin inhibited VEGFR and AKT activation, and combined with VEGFR inhibitors it killed cancer cells synergistically. Repurposing a cheap, safe, off-patent drug as a cancer helper is attractive economics. The pairing now needs animal and clinical tests to see if the dish synergy survives the body.

Catalog record

CREATORTong T. Zhao, Diane Trinh, Christina L. Addison et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012563

Browse the full library · About the Tower of Babel